Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
BioPharma DiveBen FidlerOctober 21, 2026
New follow-up results suggest Arcus drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.